Haemonetics (NYSE:HAE) Price Target Raised to $88.00 at BTIG Research

Haemonetics (NYSE:HAE) had its price objective increased by research analysts at BTIG Research from $85.00 to $88.00 in a research report issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the medical instruments supplier’s stock. BTIG Research’s target price would suggest a potential upside of 33.83% from the stock’s current price.

HAE has been the subject of several other reports. Weiss Ratings lowered Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Saturday, October 25th. Barrington Research reiterated an “outperform” rating and issued a $86.00 target price on shares of Haemonetics in a report on Tuesday, October 21st. Citigroup lowered their price target on shares of Haemonetics from $78.00 to $64.00 and set a “buy” rating on the stock in a report on Tuesday, October 7th. Raymond James Financial lowered shares of Haemonetics from a “strong-buy” rating to an “outperform” rating and reduced their price objective for the stock from $105.00 to $78.00 in a research note on Monday, August 11th. Finally, Needham & Company LLC restated a “buy” rating and issued a $68.00 target price (down from $84.00) on shares of Haemonetics in a research note on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Haemonetics has a consensus rating of “Moderate Buy” and a consensus target price of $77.10.

Haemonetics Trading Up 29.6%

Shares of NYSE HAE traded up $15.04 during mid-day trading on Thursday, reaching $65.76. The company had a trading volume of 2,522,254 shares, compared to its average volume of 828,216. Haemonetics has a 52 week low of $47.31 and a 52 week high of $94.99. The stock has a market cap of $3.17 billion, a price-to-earnings ratio of 20.01, a price-to-earnings-growth ratio of 0.91 and a beta of 0.43. The business’s 50-day moving average is $50.99 and its 200-day moving average is $61.98. The company has a current ratio of 1.72, a quick ratio of 1.04 and a debt-to-equity ratio of 1.04.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.15. Haemonetics had a return on equity of 26.64% and a net margin of 12.14%.During the same period in the previous year, the business posted $1.12 earnings per share. The firm’s revenue for the quarter was down 5.3% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Equities analysts expect that Haemonetics will post 4.55 earnings per share for the current year.

Institutional Trading of Haemonetics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Norges Bank purchased a new stake in shares of Haemonetics during the second quarter worth approximately $36,822,000. SG Capital Management LLC boosted its holdings in shares of Haemonetics by 92.5% in the second quarter. SG Capital Management LLC now owns 906,892 shares of the medical instruments supplier’s stock valued at $67,663,000 after acquiring an additional 435,660 shares in the last quarter. Citigroup Inc. lifted its position in Haemonetics by 87.3% in the first quarter. Citigroup Inc. now owns 625,565 shares of the medical instruments supplier’s stock valued at $39,755,000 after purchasing an additional 291,574 shares during the period. AQR Capital Management LLC lifted its holdings in shares of Haemonetics by 157.9% in the 2nd quarter. AQR Capital Management LLC now owns 450,248 shares of the medical instruments supplier’s stock valued at $33,390,000 after buying an additional 275,683 shares during the period. Finally, River Road Asset Management LLC grew its holdings in Haemonetics by 18.7% during the second quarter. River Road Asset Management LLC now owns 1,655,676 shares of the medical instruments supplier’s stock worth $122,586,000 after acquiring an additional 260,624 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.